arrow
C

Carmine Selleri

University Hospital San Giovanni di Dio e Ruggi d'Aragona
H指数:49
被引数:9,677

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
Personalized Venetoclax Dose Adjustment in Unfit Acute Myeloid Leukemia Patients: A Real-Life Case Series Study

个性化Venetoclax剂量调整在不适合急性髓系白血病患者中的研究:一项真实世界病例系列研究

2026-04-050
OAAI
Immunophenotypic Heterogeneity and Clonal Sweep in Acute Myeloid Leukemia Revealed by Flow Cytometry: A Case Series Study

流式细胞术揭示的急性髓系白血病免疫表型异质性与克隆扫荡:一项病例系列研究

2026-04-050
OAAI
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study

意大利阵发性睡眠性血红蛋白尿症患者中拉伏利珠单抗的临床实际应用:来自REACTION观察性研究的证据

2026-01-220
OAAI
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Venetoclax联合去甲基化药物作为异基因干细胞移植治疗复发/难治性急性髓系白血病的有效桥梁疗法:AVALON研究的一项亚组分析

2025-11-010
OAAI
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study

移植物抗宿主病流行病学、预防和管理趋势:意大利骨髓移植、造血干细胞和细胞治疗小组(GITMO)GVHD24研究

2025-11-010
PRE
Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study

利妥昔单抗与奥比妥珠单抗-苯达莫司汀在滤泡性淋巴瘤中呈现不同的免疫学动力学和巨细胞病毒再激活发生率:一项单中心病例系列研究

2025-11-010
OA
Prolonged Hematogone Expansion Is Associated with Better Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

延长Hematogone增殖与异基因造血干细胞移植受者更好的预后相关

2025-09-100
OAAI
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study

Dara-VTD诱导治疗对接受自体干细胞移植的新诊断多发性骨髓瘤患者干细胞动员结局的影响:一项多中心研究

2025-09-050
OAAI
CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience

CD38在标准化疗或靶向药物治疗的慢性淋巴细胞白血病患者中的预后作用:一项单中心真实世界研究

2025-05-080
OA
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation
2025-01-010
PRE
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
2024-04-131
PRE
Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies
2024-04-050
OAAI
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
2023-10-281
OAAI
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naive Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
2023-09-253
OAAI